| Biomarker ID | 484 |
| PMID | 20632177 |
| Year | 2010 |
| Biomarker | PSA+MMP-2+ AMACR + Methylation Status of (GSTP1 or RASSF1A) |
| Biomarker Basis | Expression Based + Methylation Based |
| Biomolecule | Protein + DNA |
| Source | Urine and Serum |
| Subjects | Humans |
| Regulation | Upregulated and Hypermethylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (AMACR): Lipid and lipoprotein metabolism, T cell receptor regulation of apoptosis, Metabolism, Peroxisome, Beta-oxidation of pristanoyl-CoA |
| Experiment | Prostate Cancer Vs No Tumor |
| Type of Biomarker | Diagnostic |
| Cohort | 115 men were chosen for the study out of which 79 had no tumor and 34 had Prostate Cancer. |
| Senstivity | 57.1% [95% CI: 29.6–81.2] |
| Specificity | 96.6% [95% CI: 80.4–99.8] |
| AUC | 0.788 ± 0.07 |
| Accuracy | NA |
| Level Of Significance | p=0.036 |
| Method Used | Methylation-specific PCR |
| Clinical | No |
| Remarks | For this model, a score was calculated as: Classification score = -4.452 + (0.004* MMP-2 level) + (0.008 * AMACR level) + (0.73 * PSA level) + (0.627 * [‘‘1’’ for positive or ‘‘0’’ for negative methylation status]) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3: MMP2: AMACR: GSTP1: RASSF1 |